Actavia Life Sciences, Inc.
RASP · OTC
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $11 | $19 | $14 | $47 |
| G&A Expenses | $60 | $106 | $35 | $54 |
| SG&A Expenses | $60 | $106 | $35 | $54 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $71 | $125 | $49 | $100 |
| Operating Income | -$71 | -$125 | -$49 | -$100 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$24 | -$23 | -$10 | -$5 |
| Pre-Tax Income | -$96 | -$148 | -$58 | -$105 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$96 | -$148 | -$58 | -$105 |
| % Margin | – | – | – | – |
| EPS | -0 | -0 | -0 | -0 |
| % Growth | 50% | -100% | 0% | – |
| EPS Diluted | -0 | -0 | -0 | -0 |
| Weighted Avg Shares Out | 771,811 | 771,811 | 578,017 | 771,811 |
| Weighted Avg Shares Out Dil | 771,811 | 771,811 | 578,017 | 771,811 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $25 | $23 | $10 | $5 |
| Depreciation & Amortization | $0 | $0 | $15 | $100 |
| EBITDA | -$71 | -$124 | -$10 | $0 |
| % Margin | – | – | – | – |